The stock of Viking Therapeutics, Inc. (NASDAQ:VKTX) has been Initiated to Outperform by Oppenheimer in its latest research note that was published on July 16. VKTX was given a price target of $12, with other Wall Street analysts also giving their reports regarding the stock. Stifel, analysts launched coverage of VKTX stock with a Buy rating, according to their flash note to investors on June 25. Analysts at SVB Leerink issued an upgrade fromMkt Perform to Outperform for the stock, in a research note that dated back to March 29.
Viking Therapeutics, Inc., which has current market capitalization of above $553 Million, published its last quarter earnings on June 30, 2019.
VKTX surged by $0.02 during the normal trading session on Thursday and reaching a high of $7.70 during the day while it closed the day at $7.35. The Viking stock had a low trading volume of 0.97 million shares on that day, which is low compared to the average daily volume of 1.27M shares. VKTX has also lost 0.94% of its value over the past 7 days. However, the stock has declined by 10.04% in the 3 months of the year. Over the past six months meanwhile, it has lost 4.79% while it has lost 3.92% year-on date. Let us now take a look at the stock’s potential support and resistance levels. The publicly traded company was seen to have slipped by -15.52% from its 3 months high price. However, taking another look at VKTX will indicate that it is trading +12.56% away from its 90-day low. Looking at the bigger picture, the Viking Therapeutics, Inc. stock has dropped by -69.38% from its 52-week high while it has surged by +12.56% from its 52-week low price.
Looking at the stock’s Technical analysis information over the past 50 days shows that its Raw Stochastic average stood at 37.79%. This figure is worse than the company’s 20-day Raw Stochastic average which currently stands at 65.6%. Over the past 20 days, Viking’s Stochastic %K stood at 84.8% while its Stochastic %D was revealed to be 83.5%.